Pathophysiology of pruritus in atopic dermatitis: An overview

Experimental Dermatology

Volumn 11, Issue 1, 2002, Pages 12-24

  Ständer, Sonja ^a   Steinhoff, Martin ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Acetylcholine; Atopic dermatitis; Nerve fibers; Neuropeptides; Pathophysiology; Proteinases; Pruritus

Indexed keywords

ACETYLCHOLINE; ANTIHISTAMINIC AGENT; ASCOMYCIN; CETIRIZINE; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; DOXEPIN; GAMMA INTERFERON; HISTAMINE; MACROLIDE; MORPHINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NALMEFENE; NALOXONE; NALTREXONE; NARCOTIC ANALGESIC AGENT; NEUROPEPTIDE; NEUROTRANSMITTER; NEUROTROPHIN 4; OPIATE ANTAGONIST; OPIATE PEPTIDE; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR; RECEPTOR; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; TACROLIMUS; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANAMNESIS; ATOPIC DERMATITIS; BASOPHIL; CANCER; CLINICAL FEATURE; CLINICAL TRIAL; CONTACT ALLERGY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ECZEMA; EOSINOPHIL; ERYTHEMA; HISTAMINE RELEASE; HUMAN; MEDIATOR; NERVE CELL STIMULATION; NERVE ENDING; NOCICEPTION; NOCICEPTIVE RECEPTOR; NONHUMAN; NONMYELINATED NERVE; PATHOPHYSIOLOGY; PERCEPTION; PHOTOTHERAPY; PRURITUS; QUALITY OF LIFE; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SKIN DEFECT; SKIN NERVE; SYMPTOM; PHYSIOLOGY;

DERMATITIS, ATOPIC; HUMANS; NOCICEPTORS; PRURITUS;

EID: 0036485026     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0625.2002.110102.x     Document Type: Review

References (191)

1. Rothman S. Physiology of itching. Physiol Rev 1941: 21: 357-381.
2. Hanifin J M, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980: 92 (Suppl.): 44-47.
3. Koblenzer C S. Itching and the atopic skin. J Allergy Clin Immunol 1999: 104: S109-S113.
4. Andrew D, Craig A D. Spinothalamic lamina I neurons selectively sensitive to histamin: A central neuronal pathway for itch. Nat Neurosci 2001: 4: 72-77.
5. Handwerker H O. Sixty years of C-fiber recordings from animal and human skin nerves: Historical notes. Prog Brain Res 1996: 113: 39-51.
6. Schmelz M, Schmidt R, Bickel A, Handwerker H O, Torebjork H E. Specific C-receptors for itch in human skin. J Neurosci 1997: 17: 8003-8008.
7. Schmelz M. A neuronal pathway for itch. Nat Neurosci 2001: 4: 8-10.
8. Tobin D, Nabarro G, De La Faille H B, Van Vloten W A, Van Der Putte S C J, Schuurman H J. Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol 1992: 90: 613-622.
9. Sugiura H, Omoto M, Hirota Y, Danno K, Uehara M. Density and fine structure of peripheral nerves in various skin lesions at atopic dermatitis. Arch Derm Res 1997: 289: 125-131.
10. Urashima R, Mihara M. Cutaneous nerves in atopic dermatitis. A histological, immunohistochemical and electron microscopic study. Virchows Arch 1998: 432: 363-370.
11. Pincelli C, Fantini F, Massimi P, Girolomoni G, Seidenari S, Giannetti A. Neuropeptides in skin from patients with atopic dermatitis: An immunohistochemical study. Br J Dermatol 1990: 122: 745-750.
12. Osterle L S, Cowen T, Rustin M H. Neuropeptides in the skin of patients with atopic dermatitis. Clin Exp Dermatol 1995: 20: 462-467.
13. Albers K M, Wright D E, Davis B M. Overexpression of nerve growth factor in epidermis of transgenic mice causes hypertrophy of peripheral nerve system. J Neurosci 1994: 14: 1422-1432.
14. Pincelli C, Sevignani C, Manfredini R. Expression and function of nerve growth factor and nerve growth factor receptor on cultured keratinocytes. J Invest Dermatol 1994: 103: 13-18.
15. Mihm MC, Soter N A, Dvorak H F, Austen K F. The structure of normal skin and the morphology of atopic eczema. J Inv Dermatol 1976: 67: 305-312.
16. Prose P H, Sedlis E. Morphologic and histochemical studies of atopic eczema in infants and children. J Invest Dermatol 1960: 34: 149-165.
17. Kaji A, Shigematsu H, Fujita K, Maeda T, Watanabe S. Parasympathetic innervation of cutaneous blood vessels by vasoactive intestinal polypeptide-immunoreactive and acetylcholinesterase-positive nerves: Histochemical and experimental study on rat lower lip. Neuroscience 1988: 25: 353.
18. Advenier C, Devillier P. Neurokinins and the skin. Allerg Immunol 1993: 25: 280-282.
19. Brain S D, Williams T J. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol 1985: 86: 855-860.
20. Wallengren J, Badendick K, Sundler F, Hakanson R, Zander E. Innervation of the skin of the forearm in diabetic patients: Relation to nerve function. Acta Derm Venereol 1995: 75: 37-42.
21. Heyer G, Vogelsang M, Hornstein O P. Acetylcholine is an inducer of itching in patients with atopic dermatitis. J Dermatol 1997: 24: 621-625.
22. Schallreuter K U. Epidermal adrenergic signal transduction as part of the neuronal network in the human epidermis. J Invest Dermatol Symp Proc 1997: 2: 37-40.
23. Röcken M, Schallreuter K, Renz H, Szentivanyi A. What exactly is 'atopy'? Exp Dermatol 1998: 7: 97-104.
24. Grando S A. Biological functions of keratinocyte cholinergic receptors. J Invest Dermatol Symp Proc 1997: 2: 41-48.
25. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev 2000: 21: 457-487.
26. Königstein H. Experimental study of itch stimuli in animals. Arch Derm Syph 1948: 57: 829-849.
27. Darsow U, Derzezga A, Fritsch N et al. Processing of histamine-induced itch in the human cerebral cortex: A correlation analysis with dermal reactions. J Invest Dermatol 2000; 115: 1029-1033.
28. Heyer G, Hornstein O P, Handwerker H O. Skin reactions and itch sensation induced by epicutaneous histamine application in atopic dermatitis and controls. J Invest Dermatol 1989: 93: 492-496.
29. Scholzen T, Armstrong C A, Bunnett N W, Luger T A, Olerud J E, Ansel J C. Neuropeptides in the skin: Interactions between the neuroendocrine and the skin immune system. Exp Dermatol 1998; 7: 81-96.
30. Steinhoff M, Armstrong C, Scholzen T, et al. Neurocutaneous control of inflammation. In: Fitzpatrick, T B, Norris, D A, Kupper, T S, eds. Immune Mechanisms in Cutaneous Disease, 2nd edn. New York: Marcel Dekker Inc., in press.
31. Ansel J C, Kaynard Ah, Armstrong C A, Olerud J, Bunnett N, Payan D. Skin-nervous system interactions. J Invest Dermatol 1996: 106: 198-204.
32. Rukwied R, Heyer G. Cutaneous reactions and sensations after intracutaneous injection of vasoactive intestinal polypeptide and acetylcholine in atopic eczema patients and healthy controls. Arch Dermatol Res 1998; 290: 198-204.
33. Heyer G, Ulmer F J, Schmitz J, Handwerker H O. Histamine-induced itch and alloknesis (itchy skin) in atopic eczema patients and controls. Acta Derm Venereol 1995: 75: 348-352.
34. Wahlgren C F. Pathophysiology of itching in urticaria and atopic dermatitis. Allergy 1992: 47: 65-75.
35. Wahlgren C F. Measurement of itch. Semin Dermatol 1995: 14: 277-284.
36. Weidner C, Klede M, Rukwied R, et al. Acute effects of Substance P and calcitonin gene-related peptide in human skin - A microdialysis study. J Invest Dermatol 2000: 115: 1015-1020.
37. Fjellner B, Hägermark Ö. Studies on pruritogenic and histamine-releasing effects of some putative peptide neurotransmitters. Acta Derm Venereol 1981: 61: 245-250.
38. Fantini F, Pincelli C, Massimi P, Giannetti A. Neuropeptide-like immunoreactivity in skin lesions of atopic dermatitis and psoriasis. Br J Dermatol 1990: 122: 838-839.
39. Pincelli C, Fantini F, Massimi P, Giannetti A. Neuropeptide Y-like immunoreactivity in Langerhans cell from patients with atopic dermatitis. Int J Neurosci 1990: 51: 219-220.
40. Anand P, Springall D R, Blank M A, Sellu D, Polak J M, Bloom S R. Neuropeptides in skin disease: Increases VIP in eczema and psoriasis but not axillary hyperhidrosis. Br J Dermatol 1991: 124: 547-549.
41. Pincelli C, Fantini F, Romualdi P, Lesa G, Giannetti A. Skin levels of vasoactive intestinal polypeptide in atopic dermatitis. Arch Dermatol Res 1991: 283: 230-232.
42. Fantini F, Pincelli C, Romualdi P, Donatini A, Giannetti A. Substance P levels are decreased in lesional skin of atopic dermatitis. Exp Dermatol 1992: 1: 127-128.
43. Giannetti A, Fantini F, Cimitan A, Pincelli C. Vasoactive intestinal polypeptide and substance P in the pathogenesis of atopic dermatitis. Acta Derm Venereol 1992: 176 (Suppl.): 90-92.
44. Bernstein J E, Parish L C, Rapaport M, Rosenbaum M M, Roenigk H H. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol 1986: 15: 504-507.
45. Ellis C N, Berberian B, Sulica V I, et al. A double-blind evaluation of topical capsaicin in pruritic psoariasis. J Am Acad Dermatol 1993: 29: 438-442.
46. Reimann S, Luger T, Metze D. Topische Anwendung von Capsaicin in der Dermatologie zur Therapie von Juckreiz und Schmerz. Hautarzt 2000: 51: 164-172.
47. Ständer S, Luger T, Metze D: Effective treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001: 44: 471-478.
48. Caterina M J, Schumacher M A, Tominaga M, Rosen T A, Levine J D, Julius D. The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature 1997: 389: 816-824.
49. Dray A: Neuropharmacological mechanisms of capsaicin and related substances. Biochem Pharmacol 1992: 44: 611-615.
50. Fjellner B, Hägermark Ö. Potentiation of histamine-induced itch and flare responses in human skin by the encephalin analogue FK 33-824, β-endorphin and morphine. Arch Derm Res 1982: 274: 29-37.
51. Bernstein J E, Grinzi R A. Butorphanol-induced pruritus antagonized by naloxone. J Am Acad Dermatol 1981: 5: 227-228.
52. Leung D V, Schneeberger E E, Gerha R S. The presence of IgE in macrophages and dendritic cells infiltrating into the skin lesions of atopic dermatitis. Clin Immunol Immunopathol 1987: 42: 328.
53. Fjellner B, Hägermark Ö. The influence of the opiate antagonist naloxone on experimental pruritus. Acta Derm Venereol 1984: 64: 73-75.
54. Stein C. The control of pain in peripheral tissue by opiods. N Engl J Med 1995: 332: 1685-1690.
55. Bernstein J E, Swift R M. Relief of intractable pruritus with naloxone. Arch Dermatol 1979: 115: 1366-1367.
56. Summerfield J A. Pain, itch and endorphins. Br J Dermatol 1981: 105: 725-726.
57. Hägermark Ö. Peripheral and central mediators of itch. Skin Pharmacol 1992: 5: 1-8.
58. Summerfield J A. Naloxone modulates the perception of itch in man. Br J Clin Pharmacol 1980: 10: 180-183.
59. Metze D, Reimann S, Beissert S, Luger T A. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999: 41: 533-539.
60. Penning J P, Samson B, Baxter A D. Reversal of epidural morphine-induced respiratory depression and pruritus with nalbuphine. Can J Anaesth 1988: 35: 559-604.
61. Bergasa N V, Alling D W, Talbot T L et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995: 123: 161-167.
62. Metze D, Reimann S, Luger T A. Effective treatment of pruritus with naltrexone, an orally active opiate antagonist. Ann N Y Acad Sci 1999: 885: 430-432.
63. Heyer G R, Hornstein O P. Recent studies of cutaneous nociception in atopic and non-atopic subject. J Dermatol 1999: 26: 77-86.
64. Heyer G R, Dotzer M, Diepgen T L, Handwerker H O. Opiate and H1 antagonists effects on histamine induced pruritus and alloknesis. Pain 1997: 73: 239-243.
65. Georgala S, Schulpis K H, Papaconstantinou E D, Stratigos J. Raised β-endorphin serum levels in children with atopic dermatitis and pruritus. J Dermatol Sci 1994: 8: 125-128.
66. Monroe E W. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 1989: 21: 135-136.
67. Banerji D, Fox R, Seleznick M, Lockey R. Controlled anti-pruritic trial of nalmefene in chronic urticaria and atopic dermatitis. J Allergy Clin Immunol 1988: 81: 252 (Abstract).
68. Burch J R, Harrison P V. Opiates, sleep and itch. Clin Exp Dermatol 1988: 13: 418-419.
69. Grando S A, Kist D A, Qui M, Dahl M V. Human keratinocytes synthesize, secrete and degrade acetylcholine. J Invest Dermatol 1993: 101: 32-36.
70. Grando S A, Zelickson B D, Kist D A. Keratinocyte muscarinic acetylcholine reports: Immunolocalisation and partial characterization. J Invest Dermatol 1995: 104: 95-100.
71. Scott A. Acetylcholine in normal and disease skin. Br J Dermatol 1962: 74: 317-322.
72. Rukwied R, Lischetzki G, McGlone F, Heyer C, Schmelz M. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: A dermal microdialysis study. Br J Dermatol 2000: 142: 114-1120.
73. Rukwied R, Heyer G. Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients. Exp Dermatol 1999: 8: 39-45.
74. Lewis T. The Blood Vessels of the Human Skin and Their Responses. London: Shaw and Sons, 1927.
75. Lewis T, Grant R T, Marvin H M. Vascular reactions of the skin to injury. Heart 1929: 14: 139-160.
76. Williams D H. Skin temperature reaction to histamine in atopic dermatitis (disseminated neurodermatitis). J Invest Dermatol 1938: 1: 119-129.
77. Johnson H H, DeOreo G A, Lascheid W P, Mitchell F. Skin histamine levels in chronic atopic dermatitis. J Invest Dermatol 1960: 34: 237-238.
78. Juhlin L. Localization and content of histamine in normal and diseased skin. Acta Derm Venereol 1967: 47: 383-391.
79. Ruzicka T, Glück S. Cutaneous histamine levels in histamine releasability from the skin in atopic dermatitis and hyper-IgE syndrome. Arch Derm Res 1983: 275: 41-44.
80. Uehara M. Reduced histamine reaction in atopic dermatitis. Arch Dermatol 1982: 118: 244-245.
81. Heyer G, Koppert W, Martus P, Handwerker H O. Histamine and cutaneous nociception: Histamine-induced responses in patients with atopic eczema, psoriasis and urticaria. Acta Derm Venereol 1998: 78: 123-126.
82. Heyer G, Hornstein O P, Handwerker H O. Reactions to intradermally injected substance P and topically applied mustard oil in atopic dermatitis patients. Acta Derm Venereol 1991: 71: 291-295.
83. Heyer G. Abnormal cutaneous neurosensitivity in atopic skin. Acta Derm Venereol 1992: 176 (Suppl.): 93-94.
84. Wahlgren C F, Hägermark Ö, Bergström R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol 1990: 122: 545-551.
85. Shelley W, Arthur R. The neurohistology and neurophysiology of the itch sensation in man. Arch Dermatol 1957: 76: 296-323.
86. Hägermark Ö, Rajka G, Bergvist U. Experimental itch in human skin elicited by rat mast cell chymase. Acta Derm Venereol 1972: 52: 125-128.
87. Bernstein J E. Capsaicin in dermatological disease. Semin Dermatol 1988: 7: 304-309.
88. Jarvikallio A, Naukkarinen A, Harvima I T, Aalto M L, Horsmanheimo M. Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema. Br J Dermatol 1997: 136: 871-877.
89. Steinhoff M, Vergnolle N, Young Sh et al. Agonists of proteinase-activated receptor 2 induced inflammation by a neurogenic mechanism. Nat Med 2000: 6: 151-158.
90. Harvima I T, Naukkarinen A, Harvima R J, Horsmanheimo M. Enzyme- and immunohistochemical localization of mast cell tryptase in psoriatic skin. Arch Dermatol Res 1989: 281: 387-391.
91. Naukkarinen A, Harvima I T, Aalto M L, Horsmanheimo M. Mast cell tryptase and chymase are potential regulators of neurogenic inflammation in psoriatic skin. Int J Dermatol 1994: 33: 361-366.
92. Damsgaard T E, Olesen A B, Sorensen F B, Thestrup-Pedersen K, Schiotz P O. Mast cells and atopic dermatitis. Stereological quantification of mast cells in atopic dermatitis and normal human skin. Arch Dermatol Res 1997: 289: 256-260.
93. Steinhoff M, Corvera C U, Thoma M S et al. Proteinase-activated receptor-2 in human skin: Tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol 1999: 8: 282-294.
94. Steinhoff M, Brzoska T, Shpacovitch V, Fastrich M, Luger T A. Proteinase-activated receptor-2 induces cytokine release and upregulation of cell adhesion molecules in human dermal microvascular endothelial cells. J Inv Dermatol 2002: in press
95. Gaspari A A, Lotze M T, Rosenberg S A, Stern J B, Katz S I. Dermatologic changes associated with interleukin 2 administration. JAMA 1987: 258: 1624-1629.
96. Wahlgren C F, Scheynius A, Hägermark Ö. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 1990: 70: 323-329.
97. Van Joost T, Stolz E, Heule F. Efficacy of low-dose cyclosporin in severe atopic skin disease. Arch Dermatol 1987: 123: 166-167.
98. Wahlgren C F, Tengvall Linder M, Hägermark Ö, Scheynius A. Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res 1995: 287: 572-580.
99. Darsow U, Scharein R, Bromm B, Ring J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumor nekrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol 1997: 137: 415-417.
100. Martin H A. Bradykinin potentiates the chemoresponsiveness of rat cutaneous C-fibre polymodal nociceptors to interleukin-2. Arch Physiol Biochem 1996: 104: 229-238.
101. Cremer B, Heimann A, Dippel E, Czarnetzki B M. Pruritogenic effects of mitogen stimulated peripheral blood mononuclear cells in atopic eczema. Acta Derm Venereol 1995: 75: 426-428.
102. Grothe C, Heese K, Meisinger C et al. Expression of interleukin-6 and its receptor in the sciatic nerve and cultured Schwann cells: Relation to 18-kD fibroblast growth factor-2. Brain Res 2000: 885: 172-181.
103. Nordlind K, Chin L B, Ahmed A A, Brakenhoff J, Theodorsson E, Liden S. Immunohistochemical localization of interleukin-6-like immunoreactivity to peripheral nerve-like structures in normal and inflammed human skin. Arch Dermatol Res 1996: 288: 431-435.
104. Lippert U, Hoer A, Möller A, Ramboer I, Cremer B, Henz B M. Role of antigen-induced cytokine release in atopic pruritus. Int Arch Allergy Immunol 1998: 116: 36-39.
105. Kanai H, Nagashima A, Hirakata E et al. The effect of azelastin hydrochloride on pruritus and leukotriene B4 in hemodialysis patients. Life Sci 1995: 57: 207-213.
106. Wahlgren C F, Hägermark Ö, Bergstrom R. Patients' perception of itch induced by histamine, compound 48/80 and wool fibres in atopic dermatitis. Acta Derm Venereol 1991: 71: 488-494.
107. Sticherling M, Bronscheuer E, Schröder J M, Christophers E. Immunohistochemical studies on NAP-1/Il-8 in contact eczema and atopic dermatitis. Arch Dermatol Res 1992: 284: 82-85.
108. Kimata H, Lindley I. Detection of plasma interleukin-8 in atopic dermatitis. Arch Dis Child 1994: 70: 119-122.
109. Hatano Y, Katagiri K, Takayasu S. Increased levels in vivo of mRNAs for IL-8 and macrophage inflammatory protein-1 alpha (MIP-1 alpha), but not of RANTES mRNA in peripheral blood mononuclear cells of patients with atopic dermatitis (AD). Clin Exp Immunol 1999: 117: 237-243.
110. Yousefi S, Hemmann S, Weber M et al. IL-8 is expressed by human peripheral blood oesinophils. Evidence for increased secretion in asthma. J Immunol 1995: 154: 5481-5490.
111. Reinhold U, Kukel S, Brzoska J, Kreysel H W. Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 1993: 29: 58-63.
112. Stevens S R, Hanifin J M, Hamilton T, Tofte S J, Cooper K D. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998: 134: 799-804.
113. Reinhold U, Wehrmann W, Kukel S, Kreysel H W. Evidence that defective interferon-gamma production in atopic dermatitis patients is due to intrinsic abnormalities. Clin Exp Immunol 1990: 79: 374-379.
114. Grewe M, Vogelsang K, Ruzicka T, Stege H, Krutmann J. Neurotrophin-4 production by human epidermal keratinocytes: Increased expression in atopic dermatitis. J Invest Dermatol 2000: 114: 1108-1112.
115. Velaquez J R, Lacy P, Moqbel R. Replenishment of RANTES mRNA expression in activated eosinophils from atopic asthmatics. Immunology 2000: 99: 591-599.
116. Akdis C A, Akdis M, Trautmann A, Blaser K. Immune regulation in atopic dermatitis. Curr Opin Immunol 2000: 12: 641-646.
117. Yamamoto J, Adachi Y, Onoue Y et al. CD 30 expression on circulation memory CD4+ T cells as a Th2-dominated situation in patients with atopic dermatitis. Allergy 2000: 55: 1011-1018.
118. Czarnetzki B M, Csato M. Comparative studies on human eosinophil migration towards platelet-activating factor and leukotriene B4. Int Arch Allergy Appl Immunol 1989: 88: 191-193.
119. Sigal C E, Valone F H, Holtzmann M J, Goetzl E J. Preferential human eosinophil chemotactic activity of the platelet-activating factor (PAF) 1-0-hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine (AGEPC). J Clin Immunol 1987: 7: 179-184.
120. Weller P F, Lee C W, Foster D W, Corey E J, Auste K F, Lewis R A. Generation and metabolism of 5-lipoxygenase pathway leukotriens by human eosinophils: Predominant production of leukotriene C4. Proc Natl Acad Sci USA 1983: 80: 7626-7630.
121. Lebel B, Venencie P Y, Saurat Jh, Soubrane C, Paupe J. Anti-IgE induced histamine release from basophils in children with atopic dermatitis. Acta Derm Venereol 1980: 92 (Suppl.): 57-59.
122. Von Der Helm D, Ring J, Dorsch W. Comparison of histamine release and prostaglandin E2 production of human basophils in atopic and normal individuals. Arch Derm Res 1987: 279: 536-542.
123. Bull H A, Courtney P F, Bunker C B, Rustin M H, Pearce F L, Dowd P M. Basophil mediator release in atopic dermatitis. J Invest Dermatol 1993: 100: 305-309.
124. Rajka G, ed. Essential Aspects of Atopic Dermatitis. Berlin: Springer Verlag, 1989: 57-69.
125. Hanifin J M. Pharmacophysiology of atopic dermatitis. Clin Rev Allergy 1986: 4: 43-65.
126. Morren M A, Przybilla B, Bamelis M, Heykants B, Reynaers A, Degreef H. Atopic dermatitis: Triggering factors. J Am Acad Dermatol 1994: 31: 467-473.
127. Werner Y. The water content of the stratum corneum in patients with atopic dermatitis. Measurement with the corneometer CM 420. Acta Derm Venereol 1986: 66: 281-284.
128. Werner Y, Lindberg M, Forslind B. Membrane-coating granules in 'dry' non-eczematous skin of patients with atopic dermatitis. A quantitative electron microscopic study. Acta Derm Venereol 1987: 67: 385-390.
129. Fartasch M, Diepgen T L. The barrier function in atopic dry skin. Disturbance of membrane-coating granule exocytosis and formation of epidermal lipids? Acta Derm Venereol 1992: 176 (Suppl.): 26-31.
130. Hägermark Ö. The pathophysiology of itch. In: Ruzicka T, ed. Handbook of Atopic Eczema. Berlin: Springer Verlag 1991: 278-286.
131. Wahlgren C F. Itch and atopic dermatitis. J Dermatol 1999: 26: 770-779.
132. Yoshiike T, Aikawa Y, Sindhvananda J et al. Skin barrier defect in atopic dermatitis: Increased permeability of the stratum corneum using dimethyl sulfoxide and theophylline. J Dermatol Sci 1993: 5: 92-96.
133. Beltrani V S. The clinical spectrum of atopic dermatitis. J Allergy Clin Immunol 1999: 104: S87-S98.
134. Hanifin J M. Basic and clinical aspects of atopic dermatitis. Ann Allergy 1984; 52: 386-393.
135. Rovensky J, Saxl O. Differences in the dynamics of sweat secretion in atopic children. J Invest Dermatol 1964: 43: 171-176.
136. Metze D, Luger T. Nervous system in the skin. In: New Basic Science in Dermatology: The Biology of the Skin, in press.
137. Fruhstorfer H, Hermanns M, Latzke L. The effects of thermal stimulation on clinical and experimental itch. Pain 1986: 24: 259-269.
138. Graham D T, Wolf S. The relation of eczema to attitude and vascular reactions of the human skin. J Laboratory Clin Med 1953: 42: 238.
139. Bendsoe N, Bjornberg A, Asnes H. Itching from wool fibres in atopic dermatitis. Contact Dermatitis 1987: 17: 21-22.
140. Ekblom A, Fjellner B, Hansson P. The influence of mechanical vibratory stimulation and transcutaneous electrical nerve stimulation on experimental pruritus induced by histamine. Acta Physiol Scand 1984: 122: 361-367.
141. Fisher A A. Nonallergic 'itch' and 'prickly' sensation to wool fibers in atopic and nonatopic persons. Cutis 1996: 58: 323-324.
142. Hogan D, Danaker C, Maibach H I. Contact dermatitis risk factors and rehabilitation. Semin Dermatol 1994: 31: 467-473.
143. Sicherer S H, Sampson H A. Food hypersensitivity and atopic dermatitis. Pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 1999: 104: 114-122.
144. Griesemer R D. Emotionally triggered disease in a dermatological practice. Psychiatr Ann 1978: 8: 49-56.
145. Niemeier V, Kupfer J, Gieler U. Observations during an itch-inducing lecture. Dermatol Psychosom 2000: 1: 15-18.
146. Fjellner B, Arnetz B B, Eneroth P, Kallner A. Pruritus during standardized mental stress. Relationship to psychoneuroendocrine and metabolic parameters. Acta Derm Venerol 1985: 65: 199-205.
147. Fjellner B, Arnetz B B. Psychological predictors of pruritus during mental stress. Acta Derm Venereol 1985: 65: 504-508.
148. Metze D, Reimann S, Luger T. Juckreiz-Symptom oder Krankheit. In: Plewig, G, Drzybilia, B, eds. Fortschritte der Praktischen Dermatologie und Venerologie. Berlin: Springer Verlag, 1997: 77-86.
149. Koblenzer C S. Psychologic and psychiatric aspects of itching. In: Bernhard, JD, ed. Itch Mechanisms and Management of Pruritus. New York: McGraw-Hill, 1994: 347-365.
150. Gupta M A, Gupta A K, Schork N J, Ellis C N. Depression modulates pruritus perception. A study of pruritus in psoriasis, atopic dermatitis and chronic idiopathic urticaria. Psychosom Med 1994: 56: 36-40.
151. Cormia F E. Experimental histamine pruritus I. Influence of physical and psychological factors on threshold reactivity. J Invest Dermatol 1952: 19: 21-34.
152. Arnetz B B, Fjellner B, Eneroth P, Kallner A. Endocrine and dermatological concomitants of mental stress. Acta Derm Venereol 1991: 156 (Suppl.): 9-12.
153. Buhk H, Muthny F A. Psychophysiologische und psychoneuroimmunologische Ergebnisse zur Neurodermitis. Hautarzt 1997: 48: 5-11.
154. Hermanns N, Scholz O B. Kognitive Einflüsse auf einen histamininduzierten Juckreiz und Quaddelbildung bei der atopischen Dermatitis. Verhaltensmod Verhaltensmed 1992: 13: 171-194.
155. Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis: A comparison of psychological and dermatological approaches to relapse prevention. J Consult Clin Psychol 1995: 63: 624-635.
156. Shenefelt P D. Hypnosis in dermatology. Arch Dermatol 2000: 136: 393-399.
157. Garg A, Chren M M, Sands L P et al. Psychological stress pertubs epidermal permeability barrier homeostasis. Arch Dermatol 2001: 137: 53-59.
158. Singh L K, Pang X, Alexacos N, Letourneau R, Theoharides T C. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substrate P: A link to neurogenic skin disorders. Brain Behav Immun 1999: 13: 225-239.
159. Schwarzer A, Scholz O B. Auswirkungen unterschiedlicher Aktivierungsbedingungen auf Patienten mit atopischer Dermatits. Verhaltensmod Verhaltensmed 1990: 11: 45-58.
160. Wahlgren C F. Itch and atopic dermatitis: Clinical and experimental studies. Acta Derm Venereol 1991: 165 (Suppl.): 1-53.
161. Hanifin J M, Ling M R, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. Part I, Efficacy. J Am Acad Dermatol 2001: 44: S28-S38.
162. Jekler J, Larkö O. Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: A paired-comparison study. J Am Acad Dermatol 1990: 22: 49-53.
163. Luger T, Van Leent E J M, Graeber M et al. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2000: 144: 788-794.
164. Neuber K, Schwartz I, Itschert G, Dieck A T. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000: 143: 385-391.
165. Hansen E R, Buus S, Deleuran M, Andersen K E. Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2000: 143: 1324-1326.
166. Hanifin J M, Schneider L C, Leung D Y et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993; 28: 189-197.
167. Hoare C, Li Wan Po A, Williams H. Systemic review of treatment for atopic eczema. Health Technol Assess 2000: 4: 1-191.
168. Aliaga A, Rodriguez M, Armijo M et al. Double-blind study of prednicarbate versus flucortin butyl ester in atopic dermatitis. Int J Dermatol 1996: 35: 131-132.
169. Maloney J M, Morman M R, Stewart D M, Tarp M D, Brown J J, Rajagopalan R. Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis. Int J Dermatol 1998: 37: 128-144.
170. Yosipovitch G, Szolar C, Hui X Y, Maibach H. High-potency topical corticosteroid rapidly decreases histamine-induced itch but not thermal sensation and pain in human beings. J Am Acad Dermatol 1996; 35: 118-120.
171. Sabroe R A, Kennedy C T, Archer C B. The effects of topical doxepin on responses to histamine, substance P, and prostaglandin E2 in human skin. Br J Dermatol 1997; 137: 386-390.
172. Drake L A, Millikan L E and the Doxepin Study Group. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Arch Dermatol 1995; 131: 1403-1408.
173. Groene D, Martus P, Heyer G. Doxepin affects acetylcholine induced cutaneous reactions in atopic eczema. Exp Dermatol 2001; 10: 110-117.
174. Shelley W B, Shelley E D, Talanin N Y. Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. J Am Acad Dermatol 1996; 34: 143-144.
175. Tamaki K. Antipruritic effect of macrolide antibiotics. J Dermatol 2000; 27: 66-67.
176. Kimata H. High dose gammaglobin treatment for atopic dermatitis. Arch Dis Child 1998; 70: 107-113.
177. Gelfand E W, Landwehr L P, Esterl B, Mazer B. Intravenous immune globulin: An alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 1996; 104: (Suppl.): 61-66.
178. Mills L B, Mordan L J, Roth H L, Winger E E, Epstein W L. Treatment of severe atopic dermatitis by topical immune modulation using dinitrochlorobenzene. J Am Acad Dermatol 2000; 42: 687-689.
179. Yoshizawa Y, Matusi H, Izaki S, Kitamura K, Maibach H I. Topical dinitrochlorobenzene therapy in the treatment of refractory atopic dermatitis: Systemic immunotherapy. J Am Acad Dermatol 2000; 42: 258-262.
180. Hanifin J M, Chan S C, Cheng J B et al. Type 4 phosphodisterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107: 51-56.
181. Fjellner B, Hägermark Ö. Experimental pruritus evoked by platelet activating factor (PAF-acether) in human skin. Acta Derm Venereol 1985; 65: 409-412.
182. Abeck D, Andersson T, Grosshans E et al. Topical application of a platelet-activating factor (PAF) antagonist in atopic dermatitis. Acta Derm Venereol 1997; 77: 449-451.
183. Andoh T, Kuraishi Y. Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in mice. Eur J Pharmacol 1998; 353: 93-96.
184. 4. Acta Physiol Scand 1984; 120: 141-143.
185. Miyoshi M, Sakurai T, Kodama S. Clinical evaluation of urinary leukotriene E4 levels in children with atopic dermatitis. Arerugi 1999; 48: 1148-1152.
186. Carruci J A, Washenik K, Weinstein A, Shupack J, Cohen D E. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998; 134: 785-786.
187. Zabawski E J, Kahn M A, Gregg L J. Treatment of atopic dermatitis with zafirlukast. Dermatol Online J 1999; 5: 10.
188. Woodmanse D P, Simon R A. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999; 83: 548-552.
189. Fogh K, Herlin T, Kragballe K. Eicosanoids in skin of patients with atopic dermatitis. Prostaglandin E2 and leuckotriene B4 are present in biologically active concentrations. J Allergy Clin Immunol 1989; 83: 450-455.
190. Watanabe T, Kuroda Y. The effect of a newly developed ointment containing eicosapentaenoic acid and docosahexaenoic acid in the treatment of atopic dermatitis. J Med Invest 1999; 46: 173-177.
191. Lieschke G J, Maher D, Cebon J et al. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Ann Intern Med 1989; 10: 357-364.